Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSH | P09668 | 1/20 | 0.51 |
| ▸ | GRPR | P30550 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 4/20 | 0.50 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30388309 | 0.97 | IL23R (0.53) | IL23RKEAP1CXCR4CTSLCTSS | |
| SCHEMBL30338573 | 0.95 | GLP1R (0.54) | IL23RKEAP1CXCR4CTSLCTSS | |
| SCHEMBL29484311 | 0.94 | GLP1R (0.56) | IL23RKEAP1CTSLCTSSCTSK | |
| SCHEMBL29670416 | 0.93 | CTSL (0.50) | IL23RCXCR4CTSLCTSSCTSK | |
| SCHEMBL29489380 | 0.93 | CTSL (0.53) | IL23RKEAP1CXCR4CTSLCTSS | |
| SCHEMBL30208638 | 0.91 | GLP1R (0.57) | IL23RCXCR4GLP1RGCGR | |
| SCHEMBL29484313 | 0.90 | NPBWR1 (0.55) | IL23RKEAP1CXCR4CTSLCTSS | |
| SCHEMBL30496771 | 0.89 | CTSL (0.50) | IL23RKEAP1CXCR4CTSLCTSS | |
| SCHEMBL31119241 | 0.89 | IL23R (0.53) | IL23RKEAP1GRPRGLP1RGCGR | |
| SCHEMBL29484310 | 0.88 | CTSL (0.53) | IL23RKEAP1CXCR4CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12458695-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12290566-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240285725-A1 | DOSING REGIMENS | SIXTH STREET LENDING PARTNERS | 2024-08-29 | — | — | US | disclosed |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2024-04-11 | — | — | US | disclosed |
| US-11903994-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | APELLIS PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | IL23R 1502/4885KEAP1 550/4885CXCR4 1353/4885 |
| US-12458695-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | IL23R 1502/4885KEAP1 550/4885CXCR4 1353/4885 |
| US-12290566-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | IL23R 1502/4885KEAP1 550/4885CXCR4 1353/4885 |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | C9, C3AR1, SERPINC1 | IL23R 2246/4885KEAP1 2723/4885CXCR4 1600/4885 |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | IL23R 1502/4885KEAP1 550/4885CXCR4 1353/4885 |
| US-11903994-B2 | Dosing regimens | C3AR1, C1QBP, C9 | IL23R 1642/4885KEAP1 547/4885CXCR4 1732/4885 |
| US-20240285725-A1 | DOSING REGIMENS | C3AR1, C1QBP, C9 | IL23R 1642/4885KEAP1 547/4885CXCR4 1732/4885 |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | IL23R 1502/4885KEAP1 550/4885CXCR4 1353/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | IL23R 859/4885KEAP1 3286/4885CXCR4 3027/4885 |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | ANPEP, ADAM8, MSTN | IL23R 1017/4885KEAP1 3607/4885CXCR4 2737/4885 |
| US-11338013-B2 | Combination therapy for C3 inhibition | C3AR1, C5, CFH | IL23R 1076/4885KEAP1 437/4885CXCR4 369/4885 |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | C9, C3AR1, SERPINC1 | IL23R 2240/4885KEAP1 2738/4885CXCR4 1561/4885 |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | CFH, CFB, HAVCR2 | IL23R 976/4885KEAP1 1861/4885CXCR4 211/4885 |
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | C5, C3AR1, C1QBP | IL23R 42/4885KEAP1 153/4885CXCR4 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.